Insmed Incorporated reported second-quarter 2026 financial results on August 6, 2026. Total company revenues reached $425.5 million, a 296% increase from the prior year period. BRINSUPRI (brensocatib) generated $309.2 million in revenue, reflecting 49% sequential growth, while ARIKAYCE contributed $116.3 million, up 8% year-over-year. The company raised its full-year 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion and reiterated ARIKAYCE guidance at $450 million to $470 million. Insmed also increased its combined peak revenue estimate for its three lead programs to more than $14 billion, driven by expectations exceeding $7 billion for BRINSUPRI and over $6 billion for TPIP. The company reported a net loss of $13.2 million, or $0.06 per share, compared to a net loss of $321.7 million in the same period last year. Insmed operates as a global biopharmaceutical company developing therapies for serious respiratory and rare diseases.

Insmed Incorporated announced positive 12-month data from its ongoing open-label extension study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The data demonstrated sustained improvement across all secondary efficacy measures, including a reduction in mortality risk status by REVEAL Lite 2.0, and showed that patients who switched from placebo to TPIP achieved similar clinical benefits to those who continued TPIP. Insmed is a global biopharmaceutical company that develops therapies for serious diseases.